Apogee Technology, Inc. to Launch Phase I Clinical Studies
Published: Nov 10, 2010
HERSHEY, Pa.--(BUSINESS WIRE)--From the lab bench at the Hershey Center for Applied Research: an experimental drug is one step closer to treating patients with cancer. Apogee Biotechnology Corporation, a Pennsylvania-based drug discovery company, is poised to begin Phase I clinical trials of ABC294640, its first-in-class sphingosine kinase inhibitor, following Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application. Sphingosine kinase controls the growth of tumors by promoting cancer cell proliferation, inflammation and new blood vessel formation.